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may involve antiapoptotic effects. The
discussion about this study focused on
the neuroprotective balance between the
degree of hypothermia and the duration
of circulatory arrest.1
An important consideration is that the
75-minute duration of circulatory arrest
in this animal study exceeds the typical
clinical range of minutes (30 –50 min-
utes).2-4 Why not study the effects of
profound hypothermia in an experimental
model that includes clinically relevant
durations of circulatory arrest? Why not
study brain apoptosis during profound
hypothermia at time intervals of 10 min-
utes within the clinical range to calibrate
the degree of hypothermia with the dura-
tion of ischemia? The answers to this
series of questions would provide addi-
tional laboratory evidence that could per-
haps guide clinical conduct of hypother-
mia for optimal neuroprotection.
This kind of pitfall may be a theme in
experimental circulatory arrest: The con-
duct of hypothermic circulatory arrest in
the laboratory setting is significantly dif-
ferent from that in the clinical setting. As
a consequence, the laboratory findings
are diluted in translation, resulting in a
laboratory– clinical divide that may slow
progress toward the optimal clinical con-
duct of circulatory arrest.
Perhaps it is time for the development
of guidelines for the laboratory study of
circulatory arrest and regional cerebral
perfusion, given the considerable current
controversy in infant perfusion manage-
ment.2-4 To my knowledge, no such
guidelines have been published. The
guidelines could follow a series of delib-
erations among both clinical and labora-
tory experts in this area to develop an-
swers to questions such as the following:
1. What is the recommended study in-
terval of circulatory arrest?
2. What depths of hypothermia should
be studied at which durations of cir-
culatory arrest?
3. What neuroprotective interventions
require further laboratory study in a
clinically relevant model?
4. How should a particular neuropro-
tective intervention best be studied
in the laboratory for maximal clini-
cal utility?
5. Which is the most clinically rele-
vant laboratory model of regional
cerebral perfusion?
6. Which are the most important ques-
tions for further study with respect
to optimizing the practice of re-
gional cerebral perfusion?
I congratulate Dr Ananiadou and col-
leagues1 on their excellent study that has
raised many thought-provoking questions.
I look forward to their feedback and the
ongoing progress in this area.
John G. T. Augoustides, MD, FASE
Department of Anesthesiology and
Critical Care
Hospital of the University of Pennsylvania
Philadelphia, Pa
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Reply to the Editor:
Although the deleterious effects of pro-
longed exposure to cardiopulmonary by-
pass on brain function and structure have
been demonstrated, neuroprotective strate-
gies, particularly deep hypothermia and
circulatory arrest (DHCA), remain an issue
of debate. This is related in part to the gap
between the experimental understanding of
brain injury and the clinical application of
various neuroprotective strategies. As sug-
gested by Dr Augoustides, this gap can be
attributed to the lack of clinically relevant
guidelines for effective laboratory study of
circulatory arrest.
Our goal was to assess one possible
mechanism of neuronal injury after DHCA.
Because apoptosis seems to involve a sub-
tle and complex cascade of events, the par-
adigm applied, although not totally clini-
cally relevant, would allow a robust
response for assessment. Further study is
clearly warranted to unravel relevant mech-
anisms and sensitive markers, which in
turn would allow us to appreciate the po-
tential clinical relevance of these experi-
mental findings. Dr Augoustides makes a
valid point for the need to develop appro-
priate guidelines that would enhance this
investigative process.
Evaluating various strategies in animal
studies to determine clinical feasibility has
been limited to large-animal models (por-
cine, canine, and ovine). These are expen-
sive, demanding, and usually performed
without neuropsychologic assessment.
Each model system, however, from cell
cultures to rats, large animals, and ulti-
mately clinical trials, has its advantages
and disadvantages, and its place in these
investigations.
Most animal models require an ex-
tended period of arrest to produce a repro-
ducible level of neuronal injury that would
facilitate elucidating the mechanisms of in-
jury and efficacy of neuroprotective inter-
ventions. Many large animal models re-
quire DHCA for at least 90 to 120 minutes
to demonstrate neurologic deficits.1,2 Al-
though such prolonged DHCA intervals
might not be considered clinically realistic,
they may be more appropriate for demon-
strating the molecular pathways behind
acute neuronal injury and thus modes of
intervention.
Study of a neuroprotective strategy
includes the appropriate selection of an
animal model and functional indices. The
model is selected with respect to the rel-
evance and feasibility of assessing the
parameters of interest. Investigations of
promising neuroprotective methods re-
quire validation (validation study), use in
experimental settings to optimize cere-
bral protection during cardiopulmonary
bypass and DHCA (performance study),
and test during routine cardiac surgery
(clinical study).
A clearer understanding of the conse-
quences of DHCA will be pivotal in clin-
ical decision-making, including when to
initiate circulatory arrest and the appro-
priate interval. Delayed cell death is of
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special interest because of the potential
for intervention. Although apoptosis is
believed to play a part in cerebral injury,
its role has generally been identified
through histologic techniques. These
snapshots do not permit a clear delinea-
tion of the timeline of apoptosis. Because
the role of apoptosis is not clear, thera-
pies have yet to be designed for the spe-
cific purpose of inhibiting apoptosis.
There are still many gaps in our knowl-
edge about how to best study cerebral out-
come. Investigations require coordinated
efforts by multiple groups, pursuing sys-
tematic, multilevel research, spanning from
cell cultures, to various animal models, and
ultimately to clinical trials.
Elizabeth O. Johnson, PhDa
Olga Ananiadou, MDb
Department of Anatomy, Histology, and
Embryologya
Department of Cardiovascular Surgeryb
University of Ioannina, School of Medicine
Ioannina, Greece
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We appreciate the thoughtful editorial written
by Dr Mitchell1 concerning our brief report.2
Aortic stenting is a new procedure. We agree
that any problems with this technology
should be discussed openly, as we tried to do
in our report. Likewise, Dr Mitchell’s com-
ments add to a vivid exchange of opinions.
Please allow us to answer the questions
posed in his first paragraph at the begin-
ning: The left carotid was accidentally
overstented for 2 mm, as said in the text,
and obviously it was an open web design;
otherwise placement of a stent in this po-
sition would have resulted in almost com-
plete overstenting of the left carotid artery.
The length of the neck is always a crucial
issue; we considered it to be longer than 2
cm both at the lesser and the greater cur-
vatures.
These technical details may be an im-
portant, but secondary, issue. However, we
doubt whether conventional open surgery
is still the method of choice in many elec-
tive operations on the descending aorta. The
sentence “In my opinion stent grafting should
be viewed as an additional surgical strategy
rather than an alternative one” brilliantly de-
scribes the attitude surgeons should have to-
ward this new technology. In contrast with
the reactions to coronary stenting decades
ago that were characterized by rejection
and opposition, we should eagerly learn to
adopt the interventional techniques to ex-
pand the traditional surgical armamentar-
ium for the best of our patients. In our
center, the decision for aortic stent grafting
is exclusively made by 3 cardiovascular
surgeons with extensive experience in open
aortic procedures. We believed stent graft-
ing to be superior in this special case because
of the significant calcifications of the aortic
wall, which may be visible in Figure 1,a.1
Meanwhile, we changed our policy in com-
parable cases to one that may combine the
advantages of open surgery and stent grafting
while avoiding the majority of drawbacks of
both methods. In several similar cases in the
last months, we implanted stent grafts
through an open approach via the aortic arch.
This procedure allows perfect control of the
supraaortic vessels and secure fixation of the
graft inside the arch by sutures, thus avoiding
endoleaks and migration. The cumbersome
distal aortic anastomosis is omitted, minimiz-
ing the operation time and risks of spinal
ischemia and bleeding. Correct expansion of
the graft and aortic pathology at the distal
end of the stent are assessed by intralumi-
nal endoscopy. Short circulatory arrest
with antegrade cerebral perfusion required
for this operation was well tolerated by all
patients.
This may be just one example how
methods developed by interventionalists
may help surgeons make a hazardous pro-
cedure a simple one. Others, most probably
in the field of interventional treatment of
valve disease, will follow. We strongly be-
lieve that surgeons should face the progress
of interventional technology critically, but
with an open mind, and try to extract the
best of these methods.
Robert Bauernschmitt, MD, PhD
Bernhard Voss, MD
Rüdiger Lange, MD, PhD
Department of Cardiovascular Surgery
German Heart Center Munich
Munich, Germany
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